Trial reportThe Journal of urology2014
Is there a role for body mass index in the assessment of prostate cancer risk on biopsy?
Trial report in The Journal of urology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Normal Weight, Overweight and Obesity Conditions Associated to Prostate Neoplasm Stages-A Systematic Review and Meta-Analysis.Biomedicines · 2025Review
- Identification of Plausible Candidates in Prostate Cancer Using Integrated Machine Learning Approaches.Current genomics · 2023Article
- Impact of modifiable lifestyle risk factors for prostate cancer prevention: a review of the literature.Frontiers in oncology · 2023Review
- Effect of body mass index on overall survival of patients with allogeneic hematopoietic stem cell transplantation.European journal of clinical nutrition · 2017Article
- Waist-hip Ratio (WHR), a Better Predictor for Prostate Cancer than Body Mass Index (BMI): Results from a Chinese Hospital-based Biopsy Cohort.Scientific reports · 2017Article
- Correlation between body mass index (BMI) and the Gleason score of prostate biopsies in Chinese population.Oncotarget · 2016Article
- Association Between the Body Mass Index and Prostate Cancer at Biopsy is Modified by Genetic Risk: A Cross-Sectional Analysis in China.Medicine · 2015Article
- The effects of serum from prostate cancer patients with elevated body mass index on prostate cancer cells in vitro.Lipid insights · 2015Article
- Correlation between Body Mass Index and Gleason Score in Men with Prostate Cancer in Southeastern Nigeria.Nigerian journal of surgery : official publication of the Nigerian Surgical Research SocietyArticle
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
purposeWe examine the role of body mass index in the assessment of prostate cancer risk. MATERIALS AND
methodsA total of 3,258 participants who underwent biopsy (including 1,902 men with a diagnosis of prostate cancer) were identified from the Selenium and Vitamin E Cancer Prevention Trial. The associations of body mass index with prostate cancer and high grade prostate cancer were examined using logistic regression, adjusting for age, race, body mass index adjusted prostate specific antigen, digital rectal examination, family history of prostate cancer, biopsy history, prostate specific antigen velocity, and time between study entry and the last biopsy. The prediction models were compared with our previously developed body mass index adjusted Prostate Cancer Prevention Trial prostate cancer risk calculator.
resultsOf the study subjects 49.1% were overweight and 29.3% were obese. After adjustment, among men without a known family history of prostate cancer, increased body mass index was not associated with a higher risk of prostate cancer (per one-unit increase in logBMI OR 0.83, p=0.54) but was significantly associated with a higher risk of high grade prostate cancer (ie Gleason score 7 or greater prostate cancer) (OR 2.31, p=0.03). For men with a known family history of prostate cancer the risks of prostate cancer and high grade prostate cancer increased rapidly as body mass index increased (prostate cancer OR 3.73, p=0.02; high grade prostate cancer OR 7.95, p=0.002). The previously developed risk calculator generally underestimated the risks of prostate cancer and high grade prostate cancer.
conclusionsBody mass index provided independently predictive information regarding the risks of prostate cancer and high grade prostate cancer after adjusting for other risk factors. Body mass index, especially in men with a known family history of prostate cancer, should be considered for inclusion in any clinical assessment of prostate cancer risk and recommendations regarding prostate biopsy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.